Efficacy and Safety of Iguratimod in Patients With Hand Osteoarthritis (ESIGO)
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Hand osteoarthritis is one of the most common arthritis, resulting in pain in finger and
thumb base joints. The disease is characterized by pain and stiffness of the affected joints
and is the most common cause of disability in aged people. Currently limited therapy options
are available. Synovial inflammation is involved in the joint pain. Iguratimod is a small
disease-modifying compound that can influence anti-inflammatory pathways in models of
rheumatoid arthritis. It has an anabolic effect on the bone metabolism of infected joint by
osteoclastogenesis inhibition and osteoblast differentiation. The investigators hypothesize
that Iguratimod will alleviate pain of patient with inflammatory hand osteoarthritis, and
that a beneficial effect of Iguratimod on pain will be accompanied by a decrease of synovial
inflammation.